Radiological diagnosis of hepatocellular carcinoma

Liver International

Volumn 28, Issue 2, 2008, Pages 189-199

  Saar, Bettina ^a   Kellner Weldon, F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

CT; HCC; Imaging methods; MRI; Ultrasound

Indexed keywords

ALPHA FETOPROTEIN; ECHO CONTRAST MEDIUM; FERUCARBOTRAN; FLUORODEOXYGLUCOSE F 18; GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOXETIC ACID; MANGAFODIPIR; SHU 508; SUPERPARAMAGNETIC IRON OXIDE;

CANCER STAGING; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 38849189317     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01655.x     Document Type: Review

References (71)

1. Fernandez MP, Redvanly RD. Primary malignant neoplasms. Radiol Clin Noth Am 1998; 36: 333-48.
2. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127: 5-16.
3. El-Serag HB, Ason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United states. Hepatology 2001; 33: 62-5.
4. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
5. Barbara L, Benzi G, Giani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors in tumour growth rate and patient survival. Hepatology 1992; 16: 132-7.
6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. Gastroenterol 2005; 40: 225-35.
7. Schafer DF, Sorrel MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
8. Hussain SM, Zondervan PE, Izermans JNM, et al. Benign versus malignant hepatic nodules: MR-imaging findings with pathologic correlation. Radiographics 2002; 22: 1023-36.
9. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep carcinogenesis: Adenomatous hyperplasia and early hepatocellular carcinoma. Hum Path 1991; 22: 172-8.
10. Choi BI, Takayasu K, Han MC. Small hepatocellular carcinomas and associated nodular lesions of the liver: Pathology, pathogenesis and imaging findings. Am J Roentgenol 1993; 160: 1177-87.
11. Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fineneedle biopsy. Hepatology 1999; 30: 889-93.
12. Bruix J, Shermann M. Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
13. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 138-45.
14. Stewart CJR, Coldewey J, Stewart IS. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol 2002; 55: 93-7.
15. Fornari F, Civardi G, Cavanna L, et al. Ultrasonically guided fine-needle aspiration biopsy: A highly diagnostic procedure or hepatic tumors. Am J Gastroenterol 1990; 85: 1009-13.
16. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16 year population based study. Hepatology 2000; 32: 842-6.
17. Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005; 20: 872-81.
18. Terminology of nodular hepatic lesions. International Working Party. Hepatology 1995; 22: 983-93.
19. Bennett GL, Krinsky GA, Abitbol RJ, et al. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. Am J Roentgenol 2002; 179: 75-80.
20. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review. Am J Gastroenterol 2006; 101: 513-23.
21. Ando E, Kuromatsu R, Tanaka M, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: Results of specialized department of liver disease. J Clin Gastroenterol 2006; 40: 942-8.
22. Burns PN. Interpreting and analyzing the Doppler examination. In: Taylor KJW, Burns PN, Wells PNT, eds. Clinical applications of Doppler ultrasound. New York, NY: Raven, 1995; 55-98.
23. Wells PNT. Basic principles and Doppler physics. In: Taylor KJW, Burns PN, Wells PNT, eds. Clinical Applications of Doppler Ultrasound. New York, NY: Raven, 1995; 1-17.
24. Lu MD, Yu XL, Li AH, et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: A multi-center study in China. Ultrasound Med Biol 2007; 33: 1736-49.
25. Chen MH, Yang W, Yan K, et al. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation. Clin Radiol 2007; 62: 752-60.
26. Kisaka Y, Hirooka M, Kumagi T, et al. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006; 26: 1241-7.
27. Maruyama H, Kobayashi S, Yoshizumi H, et al. Application of percutaneous ultrasound-guided treatment for ultrasonically invisible hypervascular hepatocellular carcinoma using microbubble contrast agent. Clin Radiol 2007; 62: 668-75.
28. Torzilli G, Palmisano A, Del Fabbro D, et al. Contrast-enhanced intraoperative ultrasonography during surgery for hepatocellular carcinoma in liver cirrhosis: Is it useful or useless? A prospective cohort study of our experience. Ann Surg Oncol 2007; 14: 1347-55.
29. Wang Z, Tang J, An L, et al. Contrast-enhanced ultrasonography for assessment of tumor vascularity in hepatocellular carcinoma. J Ultrasound Med 2007; 26: 757-62.
30. Ding H, Kudo M, Onda H, et al. Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. Am J Roentgenol 2001; 176: 661-6.
31. Numata K, Tanaka K, Kiba T, et al. Correlation between hepatic tumor index on color Doppler sonography and tumor vessels on arteriography in large hepatocellular carcinomas. Cancer Detect Prev 1999; 23: 496-505.
32. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002; 222: 89-94.
33. Tublin ME, Dodd GD III, Baron RL. Benign and malignant portal vein thrombosis: Differentiation by CT characteristics. Am J Roentenol 1997; 168: 719-23.
34. Murakami T, Kim T, Takahashi S, Nakamura H. Hepatocellular carcinoma: multidetector row helical CT. Abdom Imaging 2002; 27: 139-46.
35. Freeny PC, Baron RL, Teefey SA. Hepatocellular carcinoma: Reduced frequency of typical findings with dynamic contrastenhanced CT in a non-Asian population. Radiology 1992; 182: 143-8.
36. Iannaccone R, Piacentini F, Murakami T, et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: Helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007; 243: 423-30.
37. Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 123-48.
38. Mitsuzaki K, Yamashita Y, Ogata I, et al. Multiple-phase helical CT of the liver for detecting small hepatomas in patients with liver cirrhosis: Contrast-injection protocol and optimal timing. Am J Roentgenol 1996; 167: 753-57.
39. Yamashita Y, Mitsuzaki K, Yi T, et al. Small hepatocellular carcinoma in patients with chronic liver damage: Prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 1996; 200: 79-84.
40. Zhao H, Yao JL, Wang Y, Zhou KR. Detection of small hepatocellular carcinoma: Comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol 2007; 13: 1252-6.
41. Sahani DV, Holakere NS, Mueller PR, Zhu AX. Advanced hepatocellular Carcinoma: CT perfusion of liver and tumor tissue - initial experience. Radiology 2007; 1243: 736-43.
42. Su Q, Benner A, Hofmann WJ, et al. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchow's Archiv 1997; 431: 391-6.
43. Saeki R, Nagai H, Kaneko S, et al. Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J Hepatol 2000; 33: 99-105.
44. Matsui O, Kadoya M, Kanemyama T, et al. Benign and malignant nodules in cirrhotic livers: Distinction based on blood supply. Radiology 1991; 178: 493-7.
45. Krinksy GA, Israel G. Nondysplastic nodules that are hyperintense on T1 weighted gradient-echo MR Imaging. Am J Roentenol 2003; 180: 1023-7.
46. Semelka R, Helmberger T. Contrast agents for MR-imaging of the liver. Radiology 2001; 218: 27-38.
47. Hahn PF, Saini S. Liver specific MR imaging contrast agents. Radiol Clin North Am 1998; 36: 287-97.
48. Spinazzi A, Lorusso V, Pirovno G, et al. Multihance clinical pharmacology: Biodistribution and MR enhancement of the liver. Acad Radiol 1998; 5: 86-9.
49. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions in MRI. A multicenter comparison of Gd-EOB-DTPA with introperative findings. Radiology 2004; 230: 266-75.
50. Pirovano G, Vanzulli A, Marti-bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR-imaging in the detection and characterization of focal liver lesions. Am J Roentenol 2000; 175: 1111-20.
51. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000; 35: 25-34.
52. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenete dimeglumine (GD-BOPTA). J Magn Reson Imaging 1999; 9: 704-10.
53. Rofsky NM, Weinreb JC, Bernardino ME, et al. Hepatocellular tumors: characterization with MN-DPDP enhanced imaging. Radiology 1993; 188: 53-9.
54. Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996; 20: 69-77.
55. Coffin CM Diche T, Mahfouz AE, et al. Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999; 9: 444-9.
56. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995; 196: 481-8.
57. Namkung S, Zech CJ, Helmberger T, et al. Superparamagnetic iron oxide (SPIO) enhanced liver MRI with ferucarbotran: Efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007; 25: 755-65.
58. Yammamoto H, Yamashita Y, Yoshimatsu S, et al. Hepatocellular carcinoma in cirrhotic livers detection with unenhanced and iron-oxide enhanced MR-imaging. Radiology 1995; 196: 106-12.
59. Vogl TJ, Hammerstingl R, Schwarz W, et al. Superparamagnetic iron oxide-enhanced versus gadolinium enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996; 198: 881-7.
60. Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2005; 184: 1069-76.
61. Hussain HK, Syed I, Nghiem HV, et al. T2 weighted MR imaging in the assessment of cirrhotic liver. Radiology 2004; 230: 637-44.
62. Kondo H, Kanemasuta M, Itoh K, et al. Does T2weighted MR imaging really add no value in detection and characterization of focal lesions in cirrhotic liver? Radiology 2005; 234: 638-40.
63. Hecht E M, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: Gadolinium - enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006; 239: 439-47.
64. Holland AE, Hecht EM, Hahn WY, et al. Importance of small (≤ 20mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: Evaluation and comparison with whole explanted liver. Radiology 2005; 237: 938-44.
65. Jeong YY, Mitchell DG, Kamishima T. Small (> 20mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. Am J Roentgenol 2002; 178: 1327-34.
66. Kim YK, Lee YH, Kim CS, Han YM. Added diagnostic value of T2 weighted MR-imaging to gadolinium-enhanced three dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol 2007; Epub ahead of print.
67. Lauenstein TC, Salman K, Morreira R, et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: Center based experience. Am J Roentgenol 2007; 189: 663-70.
68. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development and gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-7.
69. Khan MA, Coms CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-7.
70. Trojan J, Schroeder O, Raedle J, et al. Fluorine -18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-9.
71. Ho CL, Chen S, Yeung DW, Cheng TK. Dual tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48: 902-9.